|
 |
SecreFloThis page contains recent news articles, when available, and an overview of SecreFlo but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The company said most of the revenue for the year came from sales of two products: rProtein and SecreFlo. President and CEO Walter C. Herlihy sad Repligen ... Bizjournals.com … : Repligen Announces Settlement of SecreFlo(TM) Arbitration. - PR … - May 10, 2005 Repligen Announces Settlement of SecreFlo(TM) Arbitration. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Repligen Announces Settlement of SecreFlo(TM) Arbitration. - May 10, 2005 WALTHAM, Mass., May 10 /PRNewswire-FirstCall/ -- Repligen Corporation today announced that the Company has resolved its dispute with its former licensor of ... $4.95 - PR Newswire - ECNext … Release: Repligen Settles With SecreFlo Licensor, Compugen Names … - May 10, 2005 Repligen Settles With SecreFlo Licensor, Compugen Names New President, CEO. from M2 Presswire. Highbeam Research – FREE Trial. Pay-Per-View - M2 Presswire - HighBeam Research Repligen Reports Third Quarter 2006 Financial Results. - Feb 9, 2006 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(R), the profits from which will be used to partially support the ... $4.95 - PR Newswire - ECNext Repligen Settles With SecreFlo Licensor, Compugen Names New … - May 10, 2005 City of Industry, CA - Biotechnology industry news provided by Financial News USA (OTC: FNWU). Biopharmaceutical company Repligen Corp. ... $4.95 - M2 Presswire - ECNext Finance; Biopharma company announces financial results - Jun 20, 2005 Total revenue for the year consisted primarily of rProtein A sales and SecreFlo sales. Gross profit for the fiscal year 2005 was $5472000 (58%) compared to ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones Finance; Biopharma company announces financial results - Jun 21, 2005 Total revenue for the year consisted primarily of rProtein A sales and SecreFlo sales. Gross profit for the fiscal year 2005 was $5472000 (58%) compared to ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Repligen Reports Fourth Quarter and Fiscal Year 2006 Financial... - Jun 8, 2006 Product revenue for fiscal year 2006 consisting of Protein A and SecreFlo(R) sales, was $12529000 compared to $9360000 for fiscal year 2005, an increase of ... RedOrbit Repligen settles royalty dispute - May 10, 2005 Approved by the US Food and Drug Administration, SecreFlo, a synthetic form ... Repligen will continue to market SecreFlo for the "next several years," the ... Boston Business Journal Repligen Reports First Quarter 2007 Financial Results. - Aug 8, 2006 Total revenue for the first quarter consisting primarily of Protein A sales and SecreFlo(R) sales was $3628000 compared to total revenue of $4239000 for the ... $4.95 - PR Newswire - ECNext FDA ACCEPTS ANTARES LICENSEE'S NDA FOR BIO-E-GEL. | Article … - Jun 1, 2006 Biotech Business; July 1, 2003 ; 700+ words ... ... trial that demonstrated that SecreFlo(TM), secretin for injection, reduced the ... randomized to receive ... Pay-Per-View - Biotech Business - HighBeam Research Repligen Reports First Quarter 2006 Financial Results. - Jul 27, 2005 Total revenue for the first quarter consisted of $4013000 of Protein A and SecreFlo(TM) sales and $226000 of research revenue. Gross profit from product ... $4.95 - PR Newswire - ECNext Repligen Reports Third Quarter Fiscal Year 2007 Financial Results. - Feb 8, 2007 Total revenue for the third quarter, consisting primarily of Protein A and SecreFlo(R) sales, was $3882000 compared to total revenue of $2988000 for the ... Free with registration - PR Newswire - AccessMyLibrary.com OTCPicks.com Daily Market Movers Digest Midday Report - Apr 8, 2008 The company also markets SecreFlo, a synthetic form of the hormone secretin, which is used as an aid in the diagnosis of certain diseases of the pancreas. ... TransWorldNews - TransWorldNews (press release) Repligen Corporation (NASDAQ:RGEN) to Release Q2 2009 - Oct 30, 2008 It markets SecreFlo directly to gastroenterologists in the United States . The Company also owns intellectual property on monoclonal antibody and antibody ... TransWorldNews - TransWorldNews (press release) GENVEC GETS FDA CLEARANCE TO RESUME PHASE II TNFERADE … - Jul 1, 2005 Biotech Business; July 1, 2003 ; 700+ words ... ... trial that demonstrated that SecreFlo(TM), secretin for injection, reduced the ... randomized to receive ... Pay-Per-View - Biotech Business - HighBeam Research Current Research on Repligen Corp. - Nov 22, 2006 It markets SecreFlo directly to gastroenterologists in the United States. The company also conducts drug development programs for diseases, ... Free with registration - M2 Presswire - AccessMyLibrary.com Repligen Reports Second Quarter 2006 Financial Results. - Nov 3, 2005 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(R), the profits from which will be used to partially support the ... $4.95 - PR Newswire - ECNext Bellwether Report .com is following Repligen Corp. - Aug 11, 2006 Repligen also sells SecreFlo, used to assess pancreas function and diagnose gastrinoma, a gastroenterological cancer. Repligen Corp is up 8% after releasing ... $4.95 - M2 Presswire - ECNext Press Release: Repligen Reports Fourth Quarter and Fiscal Year 2006 … - Jun 8, 2006 Product revenue for fiscal year 2006 consisting of Protein A and SecreFlo(R) sales, was $12529000 compared to $9360000 for fiscal year 2005, an increase of ... Pay-Per-View - PR Newswire - HighBeam Research Repligen Reports Second Quarter Fiscal Year 2007 Financial Results. - Nov 2, 2006 Total revenue for the second quarter, consisting primarily of Protein A and SecreFlo(R) sales, was $2865000 compared to total revenue of $2800000 for the ... $4.95 - PR Newswire - ECNext Press Release: Repligen Reports First Quarter 2007 Financial Results.... - Aug 8, 2006 Total revenue for the first quarter consisting primarily of Protein A sales and SecreFlo(R) sales was $3628000 compared to total revenue of $4239000 for the ... Pay-Per-View - PR Newswire - HighBeam Research Repligen's FY 2005 sees 35% sales rise.(pharmaceutial industry)(Brief... - Jun 6, 2005 ...stating that this 35% increase was nourished by sales of recombinant Protein A and SecreFlo (synthetic porcine secretin), a diagnostic form of secretin. ... $4.95 - Pharma Marketletter - ECNext Press Release: Repligen Reports Second Quarter 2006 Financial Results... - Nov 3, 2005 ...revenue and profit margin was primarily due to increased customer demand, change in product mix and decreased royalty obligation for SecreFlo(R). ... Pay-Per-View - PR Newswire - HighBeam Research Repligen May Hit "A Home Run" - Aug 21, 2006 Repligen's Protein A, to boost antibodies, and SecreFlo, to diagnose pancreatitis and gastrinoma, a rare cancer, had sales of $12.5 million in the year ... BusinessWeek Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results - Jun 12, 2008 Total revenue for the year consisted primarily of Protein A and SecreFlo® product revenue. Operating expenses for fiscal year 2008, excluding the $40170000 ... Lifescience-online Highlights of rising and falling US stocks - MarketWatch - Jul 27, 2005 ...to 70% in the quarter from 60% due to increased customer demand, a favorable change in product mix, and a decreased royalty obligation for SecreFlo. ... MarketWatch Tracking Repligen Corporation in 2007. - Mar 8, 2007 Total revenue for the third quarter, consisting primarily of Protein A and SecreFlo(R) sales, was $3882000 compared to total revenue of $2988000 for the ... $4.95 - M2 Presswire - ECNext Repligen Announces Conference Call to Provide Update on Corporate … - Apr 9, 2007 In addition, we currently market two commercial products, Protein A and SecreFlo(R), which partially fund the advancement of our development pipeline while ... $4.95 - PR Newswire - ECNext Press Release: Repligen Reports Fourth Quarter and Fiscal Year 2008 … - Jun 12, 2008 Total revenue for the year consisted primarily of Protein A and SecreFlo(R) product revenue. Operating expenses for fiscal year 2008, excluding the ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Repligen Reports Fourth Quarter and Fiscal Year 2007 … - Jun 7, 2007 Total revenue for the year consisted primarily of Protein A and SecreFlo(R) product revenue and research revenue. Gross profit on product revenue for fiscal ... Pay-Per-View - PR Newswire - HighBeam Research Repligen boosts fiscal year revenue - Jun 8, 2006 Repligen said its product revenue jumped because of higher customer demand, and decreased royalties owed for its SecreFlo product, which is marketed to ... Bizjournals.com Press Release: Repligen Corp is Added to the Bellwether Watch list. -... - Jun 13, 2007 The company also markets SecreFlo, a synthetic form of the hormone secretin, which is used as an aid in the diagnosis of ... ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: Escalon(R) Reports Third Quarter Fiscal 2008 Results. ... - May 15, 2008 Protein A and SecreFlo(R) product revenue. Operating expenses for fiscal year 2008, excluding the $40 ... PR Newswire. Article: Cree Announces Record ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Repligen Reports Third Quarter Fiscal Year 2007 … - Feb 8, 2007 Total revenue for the third quarter, consisting primarily of Protein A and SecreFlo(R) sales, was $3882000 compared to total revenue of $2988000 for the ... Pay-Per-View - PR Newswire - HighBeam Research Business notebook - May 11, 2005 Repligen said it will receive a payment of $750000 and will continue to sell SecreFlo ''under a favorable royalty structure." ... Boston Globe Press Release: Repligen Announces Conference Call to Provide Update … - Apr 9, 2007 In addition, we currently market two commercial products, Protein A and SecreFlo(R), which partially fund the advancement of our development pipeline while ... Pay-Per-View - PR Newswire - HighBeam Research Repligen Announces Conference Call of Third Quarter Fiscal Year 2007 ... - Feb 1, 2007 In addition, we currently market two commercial products, Protein A and SecreFlo(R), which partially fund the advancement of our development pipeline while ... $4.95 - PR Newswire - ECNext Press Release: Tracking Repligen Corporation in 2007. - M2 Presswire... - Mar 8, 2007 Total revenue for the third quarter, consisting primarily of Protein A and SecreFlo(R) sales, was $3882000 compared to total revenue of $2988000 for the ... Pay-Per-View - M2 Presswire - HighBeam Research Repligen Receives Orphan Drug Designation From The FDA For RG1068 … - Nov 22, 2006 In addition, we currently market two commercial products, Protein A and SecreFlo(R), which partially fund the advancement of our development pipeline while ... Medical News Today - Medical News Today (press release) Repligen Files Infringement Complaint Against Bristol-Myers Squibb... - Jan 6, 2006 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(R), the profits from which will be used to partially support the ... Free with registration - PR Newswire - AccessMyLibrary.com Repligen Initiates Phase 2 Clinical Trial of RG2417 for Bipolar … - Mar 9, 2006 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(R), the profits from which will be used to partially support the ... Free with registration - PR Newswire - AccessMyLibrary.com Repligen第一å£æ‰äº?为盈股价大涨 - Jul 28, 2005 Repligen表示，由于客户需求的上å?‡ã€?产å“?组å?ˆçš„调整和SecreFloæ?ƒåˆ©é‡‘çš„å‡?少，利润率 从原先的60%增至70%。 截至美东时间周三下å?ˆ1:04，Repligen(RGEN)股价上涨了80美 ... 新浪网 Repligen Reports Initiation of a Clinical Study of Secretin for... - Oct 30, 2006 In addition, we currently market two commercial products Protein A and SecreFlo(R), which partially fund the advancement of our development pipeline while ... Free with registration - PR Newswire - AccessMyLibrary.com Repligen and The Stanley Medical Research Institute Expand … - Oct 21, 2005 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(R), the profits from which will be used to partially support the ... Free with registration - PR Newswire - AccessMyLibrary.com Repligen Reports Initial Clinical Data for Secretin in Schizophrenia - Feb 4, 2005 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(TM), the profits from which will be used to partially support the ... RedOrbit Repligen Announces Conference Call of Second Quarter Fiscal Year … - Oct 26, 2006 In addition, we currently market two commercial products, Protein A and SecreFlo(R), which partially fund the advancement of our development pipeline while ... Free with registration - PR Newswire - AccessMyLibrary.com Repligen to Present at the Rodman & Renshaw Global Healthcare … - May 9, 2006 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(R), the profits from which will be used to partially support the ... Free with registration - PR Newswire - AccessMyLibrary.com Repligen Announces Conference Call of First Quarter Fiscal Year 2007 ... - Aug 1, 2006 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(R), the profits from which will be used to partially support the ... Free with registration - PR Newswire - AccessMyLibrary.com Repligen Initiates Clinical Trial Of Secretin For MRI Imaging Of The ... - Jun 9, 2006 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(R), the profits from which will be used to partially support the ... Medical News Today - Medical News Today (press release) Repligen Completes Manufacturing Facility Expansion. - Oct 19, 2006 In addition, we currently market two commercial products, Protein A and SecreFlo(R), which partially fund the advancement of our development pipeline while ... Free with registration - PR Newswire - AccessMyLibrary.com Bellwether Report.com Wants Your Attention Directed To Repligen … - Aug 1, 2006 Repligen also sells SecreFlo, used to assess pancreas function and diagnose gastrinoma, a gastroenterological cancer. Shares were up 26% after a federal ... Free with registration - M2 Presswire - AccessMyLibrary.com Repligen to Present at the BIO Investor Forum Wednesday, October 18,... - Oct 16, 2006 In addition, we market two commercial products, Protein A and SecreFlo(R), which partially fund the advancement of our development pipeline while supporting ... Free with registration - PR Newswire - AccessMyLibrary.com Repligen to Present at the Rodman & Renshaw 8th Annual Healthcare … - Nov 3, 2006 In addition, we market two commercial products, Protein A and SecreFlo(R), which partially fund the advancement of our development pipeline while supporting ... $4.95 - PR Newswire - ECNext Repligen and The Stanley Medical Research Institute Enter Development... - Mar 14, 2005 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(TM), the profits from which will be used to partially support the ... $4.95 - PR Newswire - ECNext Repligen Reports Initiation of a Clinical Study of Secretin in … - Oct 6, 2005 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(R), the profits from which will be used to partially support the ... $4.95 - PR Newswire - ECNext Repligen Announces Conference Call for Third Quarter Fiscal Year 2006... - Feb 2, 2006 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(R), the profits from which will be used to partially support the ... $4.95 - PR Newswire - ECNext Press Release: Repligen to Present at the Fourth Annual Needham … - May 23, 2005 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(TM), the profits from which will be used to partially support the ... Pay-Per-View - PR Newswire - HighBeam Research Repligen Announces Conference Call of Fourth Quarter and Year End … - May 20, 2005 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(TM), the profits from which will be used to partially support the ... $4.95 - PR Newswire - ECNext Karen A. Dawes Elected a Director of Repligen Corporation. - Sep 15, 2005 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(TM), the profits from which will be used to partially support the ... $4.95 - PR Newswire - ECNext Press Release: Repligen Announces Conference Call for Third Quarter … - Feb 2, 2006 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(R), the profits from which will be used to partially support the ... Pay-Per-View - PR Newswire - HighBeam Research Repligen Announces Conference Call of Third Quarter FY 2005 Results; ... - Feb 2, 2005 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(TM), the profits from which will be used to partially support the ... $4.95 - PR Newswire - ECNext Press Release: Repligen to Present at the Rodman & Renshaw 8th … - Nov 3, 2006 In addition, we market two commercial products, Protein A and SecreFlo(R), which partially fund the advancement of our development pipeline while supporting ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Repligen to Present at the BIO Investor Forum … - Oct 16, 2006 In addition, we market two commercial products, Protein A and SecreFlo(R), which partially fund the advancement of our development pipeline while supporting ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Repligen and GE Healthcare Expand Protein A Supply … - Feb 8, 2005 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(TM), the profits from which will be used to partially support the ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Repligen Files Infringement Complaint Against Bristol-... - Jan 6, 2006 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(R), the profits from which will be used to partially support the ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Repligen Announces Conference Call for First Quarter … - Jul 22, 2005 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(TM), the profits from which will be used to partially support the ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Medistem Appoints Former World Health Organization … - Aug 22, 2006 It also manufactures Protein A products, which are used in the production of monoclonal antibodies and SecreFlo, a synthetic form of the hormone secretin, ... Pay-Per-View - M2 Presswire - HighBeam Research Repligen Reports Third Quarter 2005 Financial Results; Conference... - Feb 4, 2005 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(TM), the profits from which will be used to partially support the ... $4.95 - PR Newswire - ECNext Press Release: Karen A. Dawes Elected a Director of Repligen … - Sep 15, 2005 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(TM), the profits from which will be used to partially support the ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Repligen Reports Second Quarter Fiscal Year 2007 … - Nov 2, 2006 Total revenue for the second quarter, consisting primarily of Protein A and SecreFlo(R) sales, was $2865000 compared to total revenue of $2800000 for the ... Pay-Per-View - PR Newswire - HighBeam Research Repligen Announces Conference Call for Second Quarter Fiscal Year … - Oct 27, 2005 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(R), the profits from which will be used to partially support the ... $4.95 - PR Newswire - ECNext Press Release: Repligen to Present at the Needham & Company 5th … - Jun 13, 2006 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(R), the profits from which will be used to partially support the ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Repligen Announces Conference Call for Second Quarter … - Oct 27, 2005 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(R), the profits from which will be used to partially support the ... Pay-Per-View - PR Newswire - HighBeam Research Repligen and GE Healthcare Expand Protein A Supply Agreement. - Feb 8, 2005 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(TM), the profits from which will be used to partially support the ... $4.95 - PR Newswire - ECNext Medistem Subsidiary Receives Approval to Begin Operations. - Aug 14, 2006 It also manufactures Protein A products, which are used in the production of monoclonal antibodies and SecreFlo, a synthetic form of the hormone secretin, ... $4.95 - M2 Presswire - ECNext Finance; Biopharma company reports total third quarter revenue of … - Mar 7, 2006 ...while profit margin on product revenue was impacted favorably by the decreased royalty owed for SecreFlo, our secretin product which is marketed to ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Press Release: Repligen Announces Conference Call of Fourth Quarter … - May 20, 2005 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(TM), the profits from which will be used to partially support the ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Repligen Announces Conference Call of Second Quarter … - Oct 26, 2006 In addition, we currently market two commercial products, Protein A and SecreFlo(R), which partially fund the advancement of our development pipeline while ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Current Research on Repligen Corp. - M2 Presswire | … - Nov 22, 2006 It also manufactures Protein A products, which are used in the production of monoclonal antibodies and SecreFlo, a synthetic form of the hormone secretin, ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: Repligen Announces Conference Call of Third Quarter FY... - Feb 2, 2005 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(TM), the profits from which will be used to partially support the ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Repligen Reports First Quarter 2006 Financial Results.... - Jul 27, 2005 Total revenue for the first quarter consisted of $4013000 of Protein A and SecreFlo(TM) sales and $226000 of research revenue. Gross profit from product ... Pay-Per-View - PR Newswire - HighBeam Research Medistem Appoints Former World Health Organization Microbiologist to ... - Aug 22, 2006 It also manufactures Protein A products, which are used in the production of monoclonal antibodies and SecreFlo, a synthetic form of the hormone secretin, ... $4.95 - M2 Presswire - ECNext Press Release: Repligen to Present at the Rodman & Renshaw Global … - May 9, 2006 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(R), the profits from which will be used to partially support the ... Pay-Per-View - PR Newswire - HighBeam Research Repligen Announces Conference Call for First Quarter Fiscal Year 2006... - Jul 22, 2005 Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(TM), the profits from which will be used to partially support the ... $4.95 - PR Newswire - ECNext Press Release: Repligen Reports Fourth Quarter and Fiscal Year 2005 … - May 25, 2005 Total revenue for the year consisted primarily of rProtein A(TM) sales and SecreFlo(TM) sales. Gross profit for the fiscal year 2005 was $5472000 (58%) ... Pay-Per-View - PR Newswire - HighBeam Research Repligen Corporation - Major Products & Services - Apr 23, 2005 ...particularly for pediatric patients. Its products and services include: SecreFlo. rProtein A Enbrel Synagis Herceptin Secretin CTLA4 Uridine. Pay-Per-View - Datamonitor Company Profiles - Factiva, from Dow Jones |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |